Provided by Tiger Trade Technology Pte. Ltd.

Larimar Therapeutics, Inc.

3.12
-0.4300-12.11%
Post-market: 3.140.0200+0.64%17:30 EST
Volume:2.73M
Turnover:9.05M
Market Cap:267.04M
PE:-1.60
High:3.56
Open:3.56
Low:3.12
Close:3.55
52wk High:6.91
52wk Low:1.61
Shares:85.59M
Float Shares:45.15M
Volume Ratio:1.47
T/O Rate:6.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9534
EPS(LYR):-1.3159
ROE:-78.24%
ROA:-42.99%
PB:1.92
PE(LYR):-2.37

Loading ...

Larimar Therapeutics Q3 Net Income USD -47.712 Million

Reuters
·
Nov 20

Analysts Offer Insights on Healthcare Companies: Radnet (RDNT), Palvella Therapeutics (PVLA) and Larimar Therapeutics (LRMR)

TIPRANKS
·
Nov 06

Larimar Therapeutics Q3 net loss widens

Reuters
·
Nov 05

BRIEF-Larimar Therapeutics Q3 Net Income USD -47.712 Million

Reuters
·
Nov 05

Larimar Therapeutics Q3 Basic EPS USD -0.61

THOMSON REUTERS
·
Nov 05

Larimar Therapeutics Inc - Targets Bla Submission for Q2 2026

THOMSON REUTERS
·
Nov 05

Larimar Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview

Reuters
·
Oct 24

Truist Financial Sticks to Its Buy Rating for Larimar Therapeutics (LRMR)

TIPRANKS
·
Oct 08

Do Positive Friedreich's Ataxia Study Results Shift Larimar Therapeutics’ (LRMR) Long-Term Value Proposition?

Simply Wall St.
·
Oct 04

Larimar Therapeutics : Oppenheimer Cuts Target Price to $21 From $26

THOMSON REUTERS
·
Oct 02

Analysts Are Bullish on Top Healthcare Stocks: Larimar Therapeutics (LRMR), Inventiva (IVA)

TIPRANKS
·
Sep 30

U.S. RESEARCH ROUNDUP-Electronic Arts, Kala Bio, Semtech

Reuters
·
Sep 30

Larimar Therapeutics (LRMR) Gets a Buy from JonesTrading

TIPRANKS
·
Sep 30

Leerink Partners Keeps Their Buy Rating on Larimar Therapeutics (LRMR)

TIPRANKS
·
Sep 30

Larimar Therapeutics Down Nearly 29%, on Pace for Largest Percent Decrease Since May 2023 -- Data Talk

Dow Jones
·
Sep 30

Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study

Benzinga_recent_news
·
Sep 29

BUZZ-Larimar Therapeutics tumbles on safety concerns over rare genetic disorder drug

Reuters
·
Sep 29

BRIEF-Larimar Reports Positive Long-Term Data, Updates Nomlabofusp Program for Friedreich’s Ataxia

Reuters
·
Sep 29

Larimar Therapeutics Shares Drop 52% Premarket After Co Reports Long-Term Late-Stage Data for Genetic Disorder Drug

THOMSON REUTERS
·
Sep 29

Larimar announces 25 mg, 50 mg data from OL study of nomlabofusp

TIPRANKS
·
Sep 29